Additionally, it was reported that NGR-IFNα-2a had a stronger antitumor effect and a high selectivity to target tumor vessels in comparison with IFNα-2a, allowing a decrease in its dosage, providing advantages in combating cancer and in reducing side effects [90]. This evidence concerns the gene IFNA2 and neoplasm.